UNSPSC 51343102: Brivudine

This classification denotes a pyrimidine antagonist and antiviral agent with the molecular formula C11H13BrN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2M3055079H, chemically known as uridine, 5-(2-bromovinyl)-2-deoxy-, (e)- but generally known as brivudine, which bears US NIH Compound Identifier 446727. European Medicines Agency schedules Brivudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05893MIG.

UNSPSC 51343102 Brivudine is a Commodity code for a specific antiviral pharmaceutical agent, yet the recent state and local opportunities posted under this code show minimal direct alignment with brivudine procurement itself. Instead, state and local buyers are using this code to solicit broader pharmaceutical supply and emergency medical countermeasures. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets under an Invitation for Bid process, while Seminole County, Florida posted an IFB in June 2026 for annual supplies of Naloxone and Safe Drug Deactivation Systems. The scope of work under this code spans from antibiotic and antiviral inventory provisioning for state health departments to emergency opioid-reversal and drug-disposal systems for county public health initiatives.

Recent activity is concentrated in the Southeast and Midwest, with the two most visible recent opportunities originating in Illinois and Florida. The issuing bodies are state and county health departments and public health authorities managing strategic pharmaceutical reserves and emergency medical countermeasures. The Illinois contract was awarded on a fixed-price, multi-year basis with renewal options; the Seminole County procurement required quarterly deliveries with vendor responsibility for all shipping costs, drug-free workplace certification, and E-Verify compliance, with an initial two-year term and one-year renewal option. No set-aside designations or domestic-product preferences were reported in either award. The mismatch between the Commodity code's nominal scope (brivudine specifically) and the actual solicitations under it suggests state and local procurement offices are using this code broadly for pharmaceutical supply management rather than for brivudine in isolation.